Alunbrig (brigatinib) has been approved by the European Commission for the treatment of adult patients with ALK-positive non–small cell lung cancer (NSCLC) who were previously treated with another lung cancer medicine.

In a clinical trial, patients showed 56% positive response rate and survived for 34 months on average when treated with 180-mg dose of brigatinib. Jesús Gómez-Navarro, MD, vice president, Head of Oncology Clinical Research and Development, Takeda stated, “The European Commission’s decision to approve Alunbrig for patients with ALK-positive NSCLC is a significant advancement for European patients impacted by this life-threatening disease.”

For more information see the full article at Once Live.